ACCEL Lite: The EARLY Trial (Optimal Timing of Intervention in NSTE-ACS Without Pre-Treatment)

Nov 17, 2020   |  Alison Bailey, MD, FACC; John Gorcsan, III, MD, FACC; Laurent BONELLO, MD; Arjun Majithia, MD

Podcast

Font Size
A
A
A

What is the optimal therapeutic strategy in non-ST-segment elevation acute coronary syndromes (NSTE-ACS) in patients not pretreated with P2Y12 adenosine diphosphate receptor antagonists, and why reduce the time to invasive strategy in NSTE-ACS? In this interview, John Gorcsan, Laurent Bonello, and Arjun Majithia discuss the EARLY trial (Optimal Timing of Intervention in NSTE-ACS Without Pre-Treatment).

Like what you hear? ACCEL Subscribers enjoy 20+ insider interviews like these every month, with CME/MOC credit and other exclusive benefits. Subscribe today for more, and check out what's new at www.acc.org/ACCEL

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

Clinical Topics: Acute Coronary Syndromes, Invasive Cardiovascular Angiography and Intervention

Keywords: ACCELLite, Purinergic P2Y Receptor Antagonists, Adenosine Diphosphate


< Back to Listings